Information  X 
Enter a valid email address

LiDCO Group Plc (LID)

  Print      Mail a friend       Annual reports

Tuesday 05 November, 2019

LiDCO Group Plc

Latest monitor launched in China

RNS Number : 2267S
LiDCO Group Plc
05 November 2019
 

LiDCO Group Plc

("LiDCO" or the "Company")

 

Latest monitor launched in China

LiDCOrapidv3 monitor launches in the second largest healthcare market in the world

 

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that the LiDCOrapidv3 monitor, LiDCO's latest cardiac output monitor with non-invasive technology has been launched in China at the 27th Annual Meeting of the Chinese Society of Anesthesiology (CSA2019), which was held in Hangzhou.

 

This follows the Company receiving Chinese Food and Drug Administration ("CFDA") approval in July 2019. The Company's hemodynamic LiDCOrapidv3 monitor product will be sold via LiDCO's distribution partner, Beijing Gloryway Medical Co., Ltd ("Gloryway"). Gloryway is a leading medical device sales group specialising in anaesthesia and patient monitoring with a direct commercial presence in China. Uniquely LiDCO will be the only western supplier of hemodynamic monitoring solutions that is manufacturing its product locally in China. This could be a key differentiator as the vast majority of the 22,000 hospitals in China can only procure domestically manufactured products.  China is the second largest healthcare market in the world with a five-year compound annual growth rate by value of 17% compared with 4% in the United States1.

 

Over the last few years an increasing number of clinical studies originating from China have been published, reinforcing the positive impacts of hemodynamic monitoring proven in studies elsewhere in the world.  This is helping to drive adoption of hemodynamic monitoring technologies in China, which represents a substantial opportunity for the Company.

 

The Board anticipates that this launch will be a key contributor to the Company's future international sales growth.

 

Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "We have worked with our distribution partner, Gloryway, for a number of years.  This launch is strategically important for LiDCO and we believe that this could lead to significant sales growth in this rapidly growing market for hemodynamic monitoring."

 

1 - Major healthcare markets defined as top five global markets by the World Health Organization. 6/30/2018

 

For further information, please contact:

 

LiDCO Group Plc

www.lidco.com

Matt Sassone (CEO)

Tel: +44 (0)20 7749 1500

Tim Hall (CFO)




finnCap

Tel: +44 (0)20 7600 1658

Geoff Nash / Hannah Boros (Corporate Finance)


Andrew Burdis (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 



 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

 

Increasingly clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed originally at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

 

Key Products:

 

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

 

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

 

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:

 

·    early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·    quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

 

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

 

*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

 

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

 

LiDCO's headquarters are in London and its shares are traded on AIM.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCKMMGMNDMGLZM

a d v e r t i s e m e n t